Amben

Country of origin: Russia
Pharm-Group: Fibrinolysis inhibitors

Manufacturers: Pharmzaschita (Russia)
International name: Aminomethylbenzoic acid
Synonyms: Gumbix, Pamba
Dosage forms: substance, injection solution 1%
Composition: Active substance - aminomethylbenzoic acid.
Indications for use: Bleeding caused by hyperfibrinolysis: uterine, pulmonary, renal, perioperative; in the hypocoagulation phase of DIC syndrome, with cirrhosis of the liver, peptic ulcer of the stomach and duodenum, hemorrhagic syndrome of thrombocytopenic origin.
Contraindications: Thrombophilic conditions accompanied by the development of thrombosis and thromboembolism, hypercoagulable phase of DIC syndrome, severe forms of coronary heart or brain disease, chronic renal failure, pregnancy, lactation.
Side effects: Dizziness, hypertension or hypotension (including orthostatic), nausea, vomiting, diarrhea, catarrhal effects from the upper respiratory tract.
Interaction: Compatible with glucose solutions, hydrolysates, anti-shock liquids.
Overdose: No information.
Special instructions: Before prescribing the drug, the fibrinolytic activity of the blood and fibrinogen level should be checked. With intravenous administration, monitoring of the coagulogram is necessary, especially with ischemic heart disease, after myocardial infarction, and with liver diseases. In case of cerebrovascular accidents, use with caution. The simultaneous use of large doses of the drug and other hemostatic agents (dicinone, etamsylate) can lead to the formation of blood clots.
Literature: Encyclopedia of Medicines 2004, Encyclopedia of Medicines, 2004.